Knowledge Sourcing Intelligence (KSI)
Home/Healthcare/Biotechnology/Personalized Cancer Immunotherapy Market

Personalized Cancer Immunotherapy Market - Strategic Insights and Forecasts (2026-2031)

Personalized Cancer Immunotherapy Market Share, Growth, Forecasts and Industry Trends By Therapy Type (Immune Checkpoint Inhibitors, CAR-T Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Personalized Cancer Vaccines, Monoclonal Antibodies, Cytokine-Based Therapies), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Hematological Malignancies, Others), End-User (Hospitals, Cancer Treatment Centers, Research Institutes, Specialty Clinics), and Geography

Market Size in 2026
USD 23.2 billion
Market Size in 2031
USD 41.9 billion
CAGR 2026-2031
12.5%
Study Period
2021-2031
Single User License
$3,950
Formats
PDF, Excel, PPT, Dashboard
Pages
160
Data update
2026 refresh included
Report OverviewSegmentationTable of ContentsCustomize Report

The Personalized Cancer Immunotherapy market is projected to grow at a CAGR of 12.5%, climbing to USD 41.9 billion in 2031 from USD 23.2 billion in 2026.

Highlights:

  1. 1
    The increasing incidence of different kinds of cancers, like lung, breast, colon, and blood cancers, is enhancing the need for highly specific and personalized cancer treatments. Factors such as an older population and changes in lifestyles are the main reasons behind this rising trend.
  2. 2
    CAR-T cell therapy, T-cell receptor (TCR) therapy, tumor-infiltrating lymphocytes (TILs), and personalized cancer vaccines are some of the therapies that are becoming popular in the medical field. The use of immune checkpoint inhibitors that target PD-1, PD-L1, and CTLA-4 pathways is still leading the way in clinical practice.
  3. 3
    Platforms powered by artificial intelligence and data analytics significantly contribute to the identification of different groups of patients, discovering new drugs, and forecasting how patients will respond to treatments. This is improving the productivity of the process of creating tailored immunotherapy.
Personalized Cancer Immunotherapy Market - Strategic Insights and Forecasts (2026-2031) market size forecast infographic showing growth from 2026 to 2031
Full historical and forecast dataset available in Excel and dashboard formats. Download Sample Data →

Rapid growth in the Personalized Cancer Immunotherapy Market is driven by advancements in precision medicine/biotechnology that permit individualized treatment options. The increasing prevalence of cancer is driving the demand for these therapies. The growth in cancer cases drives strong investment in research and development, innovations in technology, particularly within the areas of genomic sequencing and artificial intelligence. While high costs and complex regulatory pathways represent some of the challenges to continued growth, both innovation and clinical developments are expected to support substantial future growth in the market.

The personalized cancer immunotherapy market is growing due to the growing use of precision medicine, along with technological advances in the biotechnology sector that allow for individualized treatments. Personalized immunotherapy uses the genetic, molecular, and immune cell characteristics of a patient to create personalized treatments such as neoantigen vaccines, adoptive cell transfer, including CAR-T therapy, or immune checkpoint inhibitors, which provide more effective treatment options than traditional treatments while decreasing side effects. With the increasing global incidence of cancer and the need for less invasive and more effective treatment alternatives, the market is expected to grow. Innovative developments in the personalized cancer immunotherapy market are being supported by major pharmaceutical/biotech companies' increasing investment into R&D, along with collaborations between academic institutions and companies.  

Market Dynamics

Market Drivers

  • Rising Global Cancer Burden: The rising number and rate of people worldwide diagnosed with cancer have contributed significantly to the growth of the personalized cancer immunotherapy market. Other than older age, lack of physical activity, smoking, pollution, and hereditary traits also lead to cancer development in many cases. Such a growing number of patients has resulted in the demand for treatment solutions that are not only highly effective but also specifically designed and durable. This has led to the introduction of personalized immunotherapy methods in healthcare systems.   

  • Shift Toward Precision Medicine: Healthcare is moving towards precision medicine, where therapies will be based on an individual's genetic, molecular, and immunological profile. Personalized cancer immunotherapy is an example of this new approach and allows doctors to provide the most suitable treatments that lead to an increase in treatment effectiveness as well as a reduction in side effects. Healthcare providers, policymakers, and research institutions worldwide are supporting this change.  

  • Rapid Development of Immunotherapy Modalities: The rise and effectiveness of immunotherapy methods like CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor (TCR) therapy, and immune checkpoint inhibitors have given a huge push to the market. These advanced therapies have shown good results in some cancers, especially blood cancers. So, these outcomes have led to more research and efforts to make these therapies work for different types of solid tumors as well.  

  • Growing Role of Artificial Intelligence and Data Analytics: Artificial intelligence (AI) and machine learning are transforming cancer treatment by enabling faster drug discovery, improved patient stratification, and predictive modeling of treatment responses. These technologies allow researchers to analyze vast datasets, identify patterns, and design more effective personalized therapies, thereby enhancing overall treatment success rates.  

Personalized Cancer Immunotherapy Market - Strategic Insights and Forecasts (2026-2031) growth infographic showing CAGR and forecast window from 2026 to 2031
Full historical and forecast dataset available in Excel and dashboard formats. Download Sample Data →

Market Restraints and Opportunities

  • High Cost of Treatment: Personalized cancer immunotherapies, mainly sophisticated treatments such as CAR-T cell therapy and tailor-made vaccines, are costly because of complicated manufacturing processes, patient-specific customization, and thorough clinical validation. The cost burden not only limits access, especially in low and middle-income countries, but also raises reimbursement issues even in the most developed markets.   

  • Complex Manufacturing and Scalability Issues: Many tailor-made treatments are being developed from patient cells, and their production needs very advanced, lengthy, and highly regulated processes. The absence of standardization and the challenge in increasing production limit the adoption and increase the time for the treatment turnaround.  

  • Stringent and Evolving Regulatory Frameworks: Regulatory clearance of immunotherapies designed specifically for individuals poses quite a challenge, as it has a highly personalized nature. Differences among patients create obstacles for defining standard clinical results, which in turn extend the time frame of approval and raise the cost of compliance for firms.

  • Growing Adoption in Emerging Markets: Healthcare infrastructure and biotechnology are the key focus areas where countries in the Asia-Pacific, South America, and the Middle East are planning to invest. Market players will have new growth opportunities because of the increase in healthcare spending and government initiatives.  

Market Segmentation

By Therapy Type – CAR-T Cell Therapy       

The use of CAR-T Cell Therapies is becoming the most rapidly rising segment in the personalized cancer immunotherapy market, mainly because it adopts a very specific way of treating cancers. This form of treatment reprograms the T-cells of a patient in a way that enables them to detect and eliminate the cancer cells, thus providing outstanding results, especially in blood cancers such as leukemia and lymphoma. This segment's growth is stimulated by more frequent drug approvals from regulators, a broader range of diseases that can be treated, and ongoing improvements in cell modification techniques.   

By Cancer Type – Lung Cancer           

The lung cancer segment is growing more rapidly than other cancers in the personalized cancer immunotherapy market, mainly because lung cancer is a major cause of death worldwide and one of the most common cancers. More lung cancer patients are being treated effectively with the help of immune checkpoint inhibitors and biomarker-targeted therapies. Detailed molecular diagnostic tests and genomic analysis are improving the accuracy of patient identification, which makes the personalized immunotherapy more effective. Furthermore, the growing number of clinical trials focused on combination therapies and novel immunotherapy approaches for lung cancer is driving innovation and market growth.    

Regional Analysis

North America Market Analysis

The personalized cancer immunotherapy market in North America accounts for the largest share, which is led by factors such as advanced healthcare infrastructure, presence of many leading pharma and biotech companies, and adoption of innovative treatment approaches. The benefits to the region include significant expenditure on research and development, the presence of genomic testing, and early availability of advanced therapies such as CAR-T cells and immune checkpoint inhibitors. Besides that, the regulatory environment is very supportive, coupled with the strong reimbursement policies in certain segments, which highly contribute to the accelerated growth of the market. The United States is the major market driver in the region with its extensive clinical trial network and fast commercialization of new therapies.

South America Market Analysis

The South American personalized cancer immunotherapy market is slowly developing, as cancer cases are on the rise, the healthcare systems are being enhanced, and there is a change towards precision medicine. Even though the South American share is comparatively smaller in the global market, it is experiencing a continuous uptake in the immunotherapeutic segment, especially in metropolitan medical facilities. Nations like Brazil, Argentina, and Chile lead this progress with the development of oncology facilities and more financial resources dedicated to cancer treatment.  

Europe Market Analysis

Europe has a large and significant market that is backed by highly developed healthcare systems, a higher focus on precision medicine, and robust government backing for cancer research. Germany, the United Kingdom, and France are among the leading countries that are embracing personalized immunotherapy. The Europe region is seeing an increase in partnerships between academic institutions and biotech companies, which is a catalyst for accelerating innovation. Moreover, European regulatory authorities are supporting the emergence of advanced therapies by offering favorable frameworks, but price competitiveness and reimbursement difficulties are major concerns.

Middle East and Africa Market Analysis

The Middle East & Africa region is at a developing stage in the personalized cancer immunotherapy market. Growth is driven by increasing healthcare investments, particularly in Gulf Cooperation Council (GCC) countries, and rising awareness about innovative cancer treatments. Governments are focusing on strengthening healthcare infrastructure and expanding access to specialized care. However, limited availability of advanced diagnostic facilities, high treatment costs, and lack of skilled professionals remain key barriers to widespread adoption across many parts of the region.  

Personalized Cancer Immunotherapy Market - Strategic Insights and Forecasts (2026-2031) Regional Growth Map infographic
Full historical and forecast dataset available in Excel and dashboard formats. Download Sample Data →

Asia Pacific Market Analysis

Asia-Pacific is the region with the highest growth of the personalized cancer immunotherapy market. This is mainly due to an increase in cancer cases, better healthcare infrastructure, and higher healthcare spending. Major countries like China, Japan, and India are making large financial commitments towards biotechnology and precision medicine. The spreading of knowledge regarding new cancer therapies, with the help of government encouragement and the performance of more clinical research, leads to an increase in the market. Besides, the area provides a vast number of patients, which is very appealing for clinical trials and the introduction of international companies to the market.

SEGMENT SHARE DISTRIBUTION (ILLUSTRATIVE)
Market Share Breakdown — By Therapy Type
Unlock Exact Segment Splits →
Immune Checkpoint Inhibitors
CAR-T Cell Therapy
T-Cell Receptor (TCR) Therapy
Tumor-Infiltrating Lymphocytes (TIL) Therapy
Cancer Vaccines (Personalized / Neoantigen-Based)
Monoclonal Antibodies
Bar lengths are illustrative. The full report gives historical and forecast revenue for each segment.
HISTORICAL & FORECAST DATA TABLE (ILLUSTRATIVE)
By Therapy Type — Revenue by Year (2026–2031)
Segment202620272028202920302031CAGR (%)
Immune Checkpoint Inhibitors
CAR-T Cell Therapy
T-Cell Receptor (TCR) Therapy
Tumor-Infiltrating Lymphocytes (TIL) Therapy
Cancer Vaccines (Personalized / Neoantigen-Based)
Total Market SizeUSD 23.2 billionUSD 41.9 billion12.5%
Unlock Full Historical & Forecast Excel Databook (2026–2031)
Download Sample Excel →

List of Companies

  • F. Hoffmann-La Roche Ltd.

  • Bristol-Myers Squibb Company

  • Merck & Co., Inc.

  • AstraZeneca plc

  • Pfizer Inc.

  • Novartis AG

  • Amgen Inc.

  • Eli Lilly and Company

  • Johnson & Johnson

  • AbbVie Inc.

  • Moderna, Inc.

  • BioNTech SE  

F. Hoffmann-La Roche Ltd.        

Through its subsidiary Roche Diagnostics, the company extensively uses advanced diagnostics to create targeted therapies that are specific to patient profiles, to facilitate more successful and patient-oriented treatment results. Roche has a strong line of products in immuno-oncology, which consists of popular immune checkpoint inhibitors and targeted therapies, all of which are grounded in a wide range of research in biomarkers and genomic profiling.        

Bristol-Myers Squibb            

Bristol-Myers Squibb has a wide array of potential new drugs in its pipeline. Besides the usual therapies, its programs also focus on combination therapies, immunotherapies of the next generation, as well as cell-based treatments that are expected to enhance response rates and widen the range of treatment indications. Strengthening its position in the field of personalized oncology, the company is intensifying its efforts in strategic collaborations, clinical trials, and acquisitions. Hence, Bristol-Myers Squibb is one of the main players in the field of personalized cancer immunotherapy.

Key Developments

  • October 2026: Northwest Biotherapeutics and NHS Blood and Transplant announced a collaboration to support personalized DCVax-L production, initially involving Leeds and Oxford.

  • September 2026: Transgene and NEC reported sustained three-year disease-free survival among all 16 TG4050-treated Phase 1 patients and published clinical findings in Nature Communications.

  • August 2026: Merck and Moderna announced positive Phase 3 INTerpath-001 results, with individualized neoantigen therapy intismeran plus KEYTRUDA meeting recurrence-free and distant metastasis-free survival endpoints.

  • July 2026: Touchlight announced first-patient dosing in the UK NEOVACC personalized lung cancer vaccine trial, using its enzymatically manufactured doggybone DNA technology.

  • February 2026: Providence Therapeutics announced support for PaedNEO-VAX, a multi-site Australian clinical trial evaluating personalized mRNA cancer vaccines in children with advanced, treatment-resistant brain tumors.

  • November 2025: Evaxion A/S, a clinical-stage TechBio company focused on the development of AI-Immunology™ powered vaccines, reveals fresh results that examine immunity after administration of AI-created personalized cancer vaccine EVX-01.    

  • September 2025: Illumina elevates personalized cancer treatment through new collaborations with pharmaceutical companies for drug development. Illumina Inc. is joining forces with several international pharmaceutical companies to co-develop companion diagnostics (CDx) that will be integrated with the TruSight™ Oncology (TSO) Comprehensive genomic profiling test.     

Personalized Cancer Immunotherapy Market Scope:

Report Metric Details
Total Market Size in 2026 USD 23.2 billion
Total Market Size in 2031 USD 41.9 billion
Forecast Unit Billion
Growth Rate 12.5%
Study Period 2021 to 2031
Historical Data 2021 to 2024
Base Year 2025
Forecast Period 2026 – 2031
Segmentation Therapy Type, Cancer Type, End User, Geography
Companies
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Pfizer Inc.
  • Novartis AG
Customization Scope 15% Free Customization included with purchase — Request Custom Breakdown →
Sample & Data Access PDF Sample, Excel Databook & Analyst Briefing — Download Free Sample →

Need country-level data or a custom regional split for your target market?Request Regional Data →

Market Segmentation

By Therapy Type

  • Immune Checkpoint Inhibitors

  • CAR-T Cell Therapy

  • T-Cell Receptor (TCR) Therapy

  • Tumor-Infiltrating Lymphocytes (TIL) Therapy

  • Cancer Vaccines (Personalized / Neoantigen-Based)

  • Monoclonal Antibodies

  • Cytokine-Based Therapies

By Cancer Type

  • Lung Cancer

  • Breast Cancer

  • Colorectal Cancer

  • Melanoma

  • Prostate Cancer

  • Hematological Malignancies

  • Others

By End User

  • Hospitals

  • Cancer Treatment Centers

  • Research Institutes

  • Specialty Clinics

By Geography

North America

  • USA

  • Canada

  • Mexico

South America

  • Brazil

  • Argentina

  • Others

Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

Middle East and Africa

  • Saudi Arabia

  • UAE

  • Others

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

Table of Contents

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY THERAPY TYPE

5.1. Introduction

5.2. Immune Checkpoint Inhibitors

5.3. CAR-T Cell Therapy

5.4. T-Cell Receptor (TCR) Therapy

5.5. Tumor-Infiltrating Lymphocytes (TIL) Therapy

5.6. Cancer Vaccines (Personalized / Neoantigen-Based)

5.7. Monoclonal Antibodies

5.8. Cytokine-Based Therapies

6. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY CANCER TYPE

6.1. Introduction

6.2. Lung Cancer

6.3. Breast Cancer

6.4. Colorectal Cancer

6.5. Melanoma

6.6. Prostate Cancer

6.7. Hematological Malignancies

6.8. Others

7. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY END USER

7.1. Introduction

7.2. Hospitals

7.3. Cancer Treatment Centers

7.4. Research Institutes

7.5. Specialty Clinics

8. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. India

8.6.3. Japan

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. F. Hoffmann-La Roche Ltd.

10.2. Bristol-Myers Squibb Company

10.3. Merck & Co., Inc.

10.4. AstraZeneca plc

10.5. Pfizer Inc.

10.6. Novartis AG

10.7. Amgen Inc.

10.8. Eli Lilly and Company

10.9. Johnson & Johnson

10.10. AbbVie Inc.

10.11. Moderna, Inc.

10.12. BioNTech SE

11. APPENDIX

11.1. Currency

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology

11.6. Abbreviations

Trusted by industry leaders
AmazonABBFujifilmHitachiMcKinseyAmazonABBFujifilmHitachiMcKinsey
Report IDKSI-008429
Last updated
Pages160

Frequently asked questions

What is the projected Personalized Cancer Immunotherapy Market size by 2031?

The Personalized Cancer Immunotherapy Market is projected to reach USD 41.9 billion by 2031.

What is the projected CAGR for the Personalized Cancer Immunotherapy Market?

The Personalized Cancer Immunotherapy Market is projected to grow at a CAGR of 12.5%.

What are the primary drivers of the personalized immunotherapy market?

Advancements in precision medicine, rising cancer prevalence, and R&D investment.

What key therapeutic approaches are popular in this market?

CAR-T, TCR, TILs, personalized vaccines, and immune checkpoint inhibitors.

How do technologies like AI impact personalized immunotherapy?

AI and data analytics identify patients, discover drugs, and forecast treatment responses.

What are the main challenges in the Personalized Cancer Immunotherapy Market?

High costs and complex regulatory pathways are significant challenges.

Cite this report

Knowledge Sourcing Intelligence. (Oct 2026). Personalized Cancer Immunotherapy Market - Strategic Insights and Forecasts (2026-2031). https://www.knowledge-sourcing.com/report/personalized-cancer-immunotherapy-market

Get notified when this report is updated